Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results
Kumar P, DeJesus E, Huhn G, Sloan L, Small CB, Edelstein H, Felizarta F, Hao R, Ross L, Stancil B, Pappa K, Ha B, for the SUPPORT Study Team. Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results. BMC Infectious Diseases 2013, 13: 269. PMID: 23741991, PMCID: PMC3685599, DOI: 10.1186/1471-2334-13-269.Peer-Reviewed Original ResearchConceptsSoluble vascular adhesion molecule-1Fosamprenavir/ritonavirAbacavir/lamivudineAntiretroviral therapyD-dimerInterleukin-6Cardiovascular biomarkersWeek 96Hs-CRPWeek 4High-sensitivity C-reactive proteinInitiation of ARTTreatment-related grade 2HIV-1-infected populationVascular adhesion molecule-1Percentage of patientsTraditional risk factorsWeeks of treatmentC-reactive proteinHIV-1 RNAMajor resistance mutationsGeometric mean ratiosAdhesion molecule-1Backbone therapyEfavirenz 600